View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
July 12, 2024 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
June 27, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
May 10, 2024 |
Quarterly report which provides a continuing view of a company’s financial position |
10-Q |
Quarterly Filings |
|
|
May 10, 2024 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
May 9, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
May 9, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
May 3, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
May 3, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
May 3, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
